The major factors for the growth of the chronic kidney disease market include the increasing incidence of chronic kidney diseases, technological advancements in the diagnostic tests for kidney diseases, and rising need for early detection.
Chronic kidney disease (CKD) is a condition that causes reduced kidney function over a period of time. It may develop over many years and lead to end-stage kidney (or renal) disease (ESRD). It has become an enormous public health issue. For instance, as per a 2019 report by the Center for Disease Control and Prevention, 15% of the adults in the United States, which accounts for approximately 37 million people, are estimated to have CKD. Thus, a high number of cases of chronic kidney diseases are expected to boost the demand for the diagnosis and treatment of the products leading to the high growth of the market.
Key Market Trends
Blood Test Segment by Diagnosis is Expected to Witness a High Growth Over the Forecast Period
The major test for the diagnosis of kidney disease include a blood test and it helps to understand how well kidneys are working. The blood test measures levels of a waste product called creatinine in the blood. The glomerular filtration rate (eGFR) is estimated in order to understand how many milliliters of waste kidneys are able to filter in a minute.
Moreover, the demand for these tests are expected to increase as the incidence of CKD is high and growing in many parts of the world. The global prevalence of end-stage renal diseases (ESRD) is high and increasing at a significant rate. In 2017, 697·5 million cases of all-stage CKD were recorded, for a global prevalence of 9·1%, as per the Global Burden of Disease Study 2017. It is found that chronic kidney diseases (CKD) may develop over many years leading to ESRD and lead to kidney failure.
Additionally, As per a 2018 report by the L. Y. Wong et al., published in International Journal of Nephrology, from 2007 to 2017, the prevalence of CKD increased from approximately 12% to 17% in Singapore and is further expected to increase to approximately 24% by 2035. Hence, owing to the rising prevalence of chronic kidney diseases the market is expected to witness high growth over the forecast period.
North America is Expected to Hold Largest Market Share over the Forecast Period
The United States is expected to be the largest chronic kidney disease market owing to the rising incidence of Chronic Kidney Diseases and the presence of better healthcare infrastructure. As per, the National Institute of Diabetes and Digestive and Kidney Disease, the prevalence of Chronic Kidney Disease (CKD) in the United States(US) is about 14%.
The prevalence of CKD is approximately 32% in the population above age 60 years which occupies more than 15% of the population of the US. More than 661,000 Americans have kidney failure. This figure has only increased in recent years. Furthermore, diagnostic companies are moreover focusing on the technological advancements in order to fasten the diagnosis of the disease. In addition, there is also a rising prevalence of diseases such as diabetes and cardiovascular diseases which are expected to boost the demand for the products over the forecast period.
The market studied is a fragmented market owing to the presence of many major market players. Some of the market players are Abbott Laboratories, Amgen Inc, AstraZeneca Plc, Beckman Coulter, F. Hoffmann-La Roche Ltd, GlaxoSmithKline Plc, Pfizer Inc., Siemens Healthineers, Sysmex Corporation, and Teva Pharmaceutical Industries Ltd.
Reasons to Purchase this report:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support